| Literature DB >> 19211253 |
Elizabeth A Harker1, Douglas S Daniels, Danielle A Guarracino, Alanna Schepartz.
Abstract
We previously described a series of 3(14)-helical beta-peptides that bind the hDM2 protein and inhibit its interaction with a p53-derived peptide in vitro. Here we present a detailed characterization of the interaction of these peptides with hDM2 and report two new beta-peptides in which non-natural side chains have been substituted into the hDM2-recognition epitope. These peptides feature both improved affinity and inhibitory potency in fluorescence polarization and ELISA assays. Additionally, one of the new beta-peptides also binds the hDM2-related protein, hDMX, which has been identified as another key therapeutic target for activation of the p53 pathway in tumors.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19211253 PMCID: PMC2926950 DOI: 10.1016/j.bmc.2009.01.039
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641